FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2959354651> ?p ?o ?g. }

• W2959354651 abstract "4097 Background: MGC is a chemosensitive tumour. According to the Norton-Simon hypothesis, a reduction of tumor burden could best be achieved by shortening the interval between the cycles, and the resistance might be overcome by switching from initial chemotherapy to a new, non cross-resistant one. We previously reported on the high efficacy of a new strategy using 2 sequential, non cross-resistant chemotherapy regimens in MGC (Cancer Chemother Pharmacol 11 Jan; 67 (1): 41-8). Aim of this study is to evaluate this therapeutic approach in a larger case series. Methods: 43 patients (pts) treated at our centre from November 04 to April 11 were included. All pts were chemo-naïve and received 4 cycles of TCF-dd (see reference above for doses) every 2 weeks. Subsequently and irrespective of their response, they received 4 cycles of COFFI (see reference above ) every 2 weeks. In both regimens pegfilgrastim 6 mg sc on day 3 was included. Results: Median age: 63; 74% male. PS 0-1. After the first regimen (TCF-dd) 43 pts were evaluable for response.We registered 3 CR, 27 PR, 7 SD, 5 PD and 1 not evaluable for an ORR at ITT of 70% (95% CI, 58-85). All pts proceeded to the second regimen (COFFI) and 40 pts were evaluable for response. The 3 CR observed after TCF-dd were maintained. Among the 27 pts with PR after TCF-dd, 2 achieved CR, 14 improved the response, 6 maintained PR, 3 progressed. Among the 7 pts with SD after TCF-dd, 1 achieved CR, 3 achieved PR, 2 progressed and 1 is not valuable. Among the 5 pts with PD after TCF-dd, 1 achieved CR, 4 achieved RP. After COFFI we observed 5 CR, 21 PR, 9 SD and 5 PD. The ORR in the 40 pts was 60% (95% CI, 50-80). Considering both regimen ORR was 93%. mTTP was 12.1 months (95% CI, 8,1-16,2). mOS was 16.1 months (95% CI, 12.7-21.6). At Dec '11, 4 out of 8 pts who achieved CR are alive and disease free. Most frequent G3-4 toxicities were: astenia (32%), neutropenia (35%), anemia (14%), neurotoxicity (21%). Conclusions: The study confirms that a sequential dose-dense strategy using TCF-dd followed by COFFI is feasible and highly effective and deserves to be tested in a randomized study which is on going." @default.
• W2959354651 created "2019-07-23" @default.
• W2959354651 creator A5013554030 @default.
• W2959354651 creator A5023171492 @default.
• W2959354651 creator A5039987253 @default.
• W2959354651 creator A5040541120 @default.
• W2959354651 creator A5041597689 @default.
• W2959354651 creator A5050668592 @default.
• W2959354651 creator A5053400405 @default.
• W2959354651 creator A5053886331 @default.
• W2959354651 creator A5067193136 @default.
• W2959354651 creator A5069893430 @default.
• W2959354651 creator A5083123006 @default.
• W2959354651 creator A5084034066 @default.
• W2959354651 creator A5087655805 @default.
• W2959354651 date "2012-05-20" @default.
• W2959354651 modified "2023-09-28" @default.
• W2959354651 title "Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by oxaliplatin, folinic acid, 5-fluorouracil, and irinotecan (COFFI) in locally advanced or metastatic gastric cancer (MGC)." @default.
• W2959354651 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.4097" @default.
• W2959354651 hasPublicationYear "2012" @default.
• W2959354651 type Work @default.
• W2959354651 sameAs 2959354651 @default.
• W2959354651 citedByCount "0" @default.
• W2959354651 crossrefType "journal-article" @default.
• W2959354651 hasAuthorship W2959354651A5013554030 @default.
• W2959354651 hasAuthorship W2959354651A5023171492 @default.
• W2959354651 hasAuthorship W2959354651A5039987253 @default.
• W2959354651 hasAuthorship W2959354651A5040541120 @default.
• W2959354651 hasAuthorship W2959354651A5041597689 @default.
• W2959354651 hasAuthorship W2959354651A5050668592 @default.
• W2959354651 hasAuthorship W2959354651A5053400405 @default.
• W2959354651 hasAuthorship W2959354651A5053886331 @default.
• W2959354651 hasAuthorship W2959354651A5067193136 @default.
• W2959354651 hasAuthorship W2959354651A5069893430 @default.
• W2959354651 hasAuthorship W2959354651A5083123006 @default.
• W2959354651 hasAuthorship W2959354651A5084034066 @default.
• W2959354651 hasAuthorship W2959354651A5087655805 @default.
• W2959354651 hasConcept C121608353 @default.
• W2959354651 hasConcept C126322002 @default.
• W2959354651 hasConcept C143998085 @default.
• W2959354651 hasConcept C2776694085 @default.
• W2959354651 hasConcept C2778239845 @default.
• W2959354651 hasConcept C2779804826 @default.
• W2959354651 hasConcept C2780259306 @default.
• W2959354651 hasConcept C2780456651 @default.
• W2959354651 hasConcept C2780962732 @default.
• W2959354651 hasConcept C2781190966 @default.
• W2959354651 hasConcept C526805850 @default.
• W2959354651 hasConcept C71924100 @default.
• W2959354651 hasConceptScore W2959354651C121608353 @default.
• W2959354651 hasConceptScore W2959354651C126322002 @default.
• W2959354651 hasConceptScore W2959354651C143998085 @default.
• W2959354651 hasConceptScore W2959354651C2776694085 @default.
• W2959354651 hasConceptScore W2959354651C2778239845 @default.
• W2959354651 hasConceptScore W2959354651C2779804826 @default.
• W2959354651 hasConceptScore W2959354651C2780259306 @default.
• W2959354651 hasConceptScore W2959354651C2780456651 @default.
• W2959354651 hasConceptScore W2959354651C2780962732 @default.
• W2959354651 hasConceptScore W2959354651C2781190966 @default.
• W2959354651 hasConceptScore W2959354651C526805850 @default.
• W2959354651 hasConceptScore W2959354651C71924100 @default.
• W2959354651 hasLocation W29593546511 @default.
• W2959354651 hasOpenAccess W2959354651 @default.
• W2959354651 hasPrimaryLocation W29593546511 @default.
• W2959354651 isParatext "false" @default.
• W2959354651 isRetracted "false" @default.
• W2959354651 magId "2959354651" @default.
• W2959354651 workType "article" @default.